Literature DB >> 15893853

Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations.

F M E Wagenlehner1, W Weidner, K G Naber.   

Abstract

Bacterial urinary tract infections (UTIs) are frequent infections in the nosocomial setting. Nosocomial UTIs are almost exclusively complicated UTIs, although the complicating factors may be very heterogenous. The bacterial spectrum of nosocomial UTIs is broad and antibiotic resistance is common. The results of international and national surveillance studies on the bacterial spectrum and antibiotic resistance of nosocomial uropathogens are provided. The treatment of nosocomial UTIs encompasses treatment of the complicating factors as well as antimicrobial chemotherapy. At least in serious UTIs, adequate initial antibiotic therapy results in lower mortality. Therefore, the initial antibiotic regimen must provide sufficient antibiotic cover. However, this can only be achieved if the bacterial spectrum and antibiotic resistance patterns of uropathogens in the institution are followed continuously. Provisional microbiological findings, such as reports on Gram stain or certain biochemical results, can lead to early stratification of pathogens and allow more tailored empiric antibiotic therapy. Antibiotic therapy of nosocomial UTIs has to consider two different aspects: (1) therapeutic success in the individual patient; and (2) prevention of emergence of antibiotic-resistant mutants. The emergence of resistance can possibly be lowered by adequate drug selection and dosing. Increasing antibiotic resistance requires more prudent use of antimicrobial drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893853     DOI: 10.1016/j.jhin.2004.12.017

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  9 in total

Review 1.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model.

Authors:  Susan M Lehman; Rodney M Donlan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

3.  Uropathogens and host characteristics.

Authors:  James H Tabibian; Jeffrey Gornbein; Arash Heidari; Sarah L Dien; Valerie H Lau; Puneet Chahal; Bernard M Churchill; David A Haake
Journal:  J Clin Microbiol       Date:  2008-10-08       Impact factor: 5.948

4.  Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.

Authors:  K G Naber; L Llorens; K Kaniga; P Kotey; D Hedrich; R Redman
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

5.  Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya.

Authors:  Samuel Kariuki; Gunturu Revathi; Nyambura Kariuki; John Kiiru; Joyce Mwituria; Charles A Hart
Journal:  BMC Microbiol       Date:  2006-12-15       Impact factor: 3.605

6.  Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.

Authors:  Agnès Meybeck; Jean-Damien Ricard; Guilène Barnaud; Mathieu Eveillard; Guillaume Chevrel; Roman Mounier; Didier Dreyfuss
Journal:  BMC Infect Dis       Date:  2008-05-17       Impact factor: 3.090

7.  Prospective evaluation of the efficacy of antibiotic prophylaxis before cystoscopy.

Authors:  Kamil Cam; Ali Kayikci; Ali Erol
Journal:  Indian J Urol       Date:  2009-04

8.  [Urinary tract infections in chronic renal failure patients hospitalized in nephrology department: bacteriological profile and risk factors].

Authors:  Abdeljalil Chemlal; Fatiha Alaoui Ismaili; Ilham Karimi; Ryme Elharraqui; Nawal Benabdellah; Samira Bekaoui; Intissar Haddiya; Yassamine Bentata
Journal:  Pan Afr Med J       Date:  2015-02-04

9.  Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients.

Authors:  Patricia Cornejo-Juárez; Diana Vilar-Compte; Alejandro García-Horton; Marco López-Velázquez; Silvio Ñamendys-Silva; Patricia Volkow-Fernández
Journal:  BMC Infect Dis       Date:  2016-06-10       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.